Our Company

Targeting Unmet Disease Through Development of Best-in-Class Therapies

We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully designed MET409, our lead product candidate, to be an optimized, next-generation FXR agonist that we are initially developing as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.

NASH is projected to be the leading cause of liver transplant by the end of 2020.

Since our founding in 2014, we invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities give us insight into disease targets and mechanisms and enable us to quickly and purposefully design drugs with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed our lead product candidate, MET409, as a novel FXR agonist and have identified a potential role for it in the treatment of NASH, IBS-D and IBD. MET409 was purposefully designed to be a non-bile acid, sustained engagement FXR agonist with high potency that could be dosed orally once-daily.

Our goal is to become a leading biopharmaceutical company discovering, developing and commercializing innovative drugs that materially benefit patients with liver and GI diseases.